Corneal collagen crosslinking
SCHWIND eye-tech-solutions says the company is the first and only manufacturer of excimer laser systems to offer the integrated SCHWIND CXL-365 vario system for corneal collagen crosslinking (CXL). 'CXL using ultraviolet A (UVA) light and riboflavin (vitamin B2) was introduced as a clinical application to stabilise the cornea by inducing crosslinks within and between collagen fibres. CXL has been investigated extensively and has been shown clinically not only to arrest the progression of keratoconic or post-LASIK ectasia but also to exert a moderately positive effect on visual status,' said a company spokeswoman.
Latest Articles
Beyond the Numbers
Empowering patient participation fosters continuous innovation in cataract surgery.
Thinking Beyond the Surgery Room
Practice management workshop focuses on financial operations and AI business applications.
Aid Cuts Threaten Global Eye Care Progress
USAID closure leads retreat in development assistance.
Supplement: ESCRS Clinical Trends Series: Presbyopia
Nutrition and the Eye: A Recipe for Success
A look at the evidence for tasty ways of lowering risks and improving ocular health.
New Award to Encourage Research into Sustainable Practices
Sharing a Vision for the Future
ESCRS leaders update Trieste conference on ESCRS initiatives.
Extending Depth of Satisfaction
The ESCRS Eye Journal Club discuss a new study reviewing the causes and management of dissatisfaction after implantation of an EDOF IOL.
Conventional Versus Laser-Assisted Cataract Surgery
Evidence favours conventional technique in most cases.
AI Scribing and Telephone Management
Automating note-taking and call centres could boost practice efficiency.